| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705288 | Ophthalmology | 2017 | 8 Pages |
Abstract
This is the first demonstration of OCTA in iris tumors. OCTA may provide a dye-free, no-injection, cost-effective method for monitoring a variety of tumors, including iris melanocytic lesions, for growth and vascularity. This could be helpful in evaluating tumors for malignant transformation and response to treatment. Penetration of the OCT beam remains a limitation for highly pigmented tumors, as does the inability to image the entire iris in a single field.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Alison H. MD, PhD, Yan PhD, Chen D. MSc, Yali PhD, ByungKun MEng, Lennart MSc, Andreas PhD, James G. PhD, Charles R. MD, David MD, PhD,